Exondys

Known as: Exondys 51 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2018
02420132018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
T patent output at universities continued to climb, with the University of California system again topping our list (Table 1… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2017
2017
207 an ineffective drug that is ultimately found to be unsafe) and type 2 errors (failing to approve a safe drug that is… (More)
Is this relevant?
Review
2017
Review
2017
through its accelerated approval review track. This pathway, which dates back to the early 1990s, was designed as a response to… (More)
Is this relevant?
Review
2017
Review
2017
The US Food and Drug Administration (FDA) has primary responsibility for oversight of every drug, biologic, andmedicaldevicesold… (More)
Is this relevant?
2016
2016
Exondys 51 is the first therapy for Duchenne muscular dystrophy (DMD) to have been granted accelerated approval by the FDA… (More)
Is this relevant?
Review
2016
Review
2016
Eteplirsen (Exondys 51) is an antisense oligonucleotide designed to induce exon 51 skipping that is developed by Sarepta… (More)
Is this relevant?
Review
2016
Review
2016
  • Nature Biotechnology
  • 2016
VOLUME 34 NUMBER 11 NOVEMBER 2016 NATURE BIOTECHNOLOGY O 19 September, the US Food and Drug Administration (FDA) granted… (More)
Is this relevant?
Review
2016
Review
2016
  • Nature Medicine
  • 2016
NATURE MEDICINE VOLUME 22 | NUMBER 11 | NOVEMBER 2016 1193 On 19 September, the US Food and Drug Administration (FDA) granted… (More)
Is this relevant?
Review
2016
Review
2016
  • The Medical letter on drugs and therapeutics
  • 2016
 
Is this relevant?
Review
2013
Review
2013
Duchenne muscular dystrophy is a fatal neuromuscular disorder affecting around one in 3,500-5,000 male births that is… (More)
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?